Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease  

在线阅读下载全文

作  者:Lukas Hartl Joshua Elias Gerhard Prager Thomas Reiberger Lukas W Unger 

机构地区:[1]Division of Gastroenterology and Hepatology,Department of Internal Medicine III,Medical University of Vienna,Vienna A-1090,Austria [2]Vienna Hepatic Hemodynamic Lab,Medical University of Vienna,Vienna A-1090,Austria [3]Cambridge Institute of Therapeutic Immunology and Infectious Disease,Jeffrey Cheah Biomedical Centre,University of Cambridge,Cambridge CB20AW,United Kingdom [4]Division of Gastroenterology and Hepatology,Department of Medicine,University of Cambridge,Addenbrooke’s Hospital,Cambridge CB20QQ,United Kingdom [5]Division of Visceral Surgery,Department of General Surgery,Medical University of Vienna,Vienna A-1090,Austria

出  处:《World Journal of Gastroenterology》2021年第19期2281-2298,共18页世界胃肠病学杂志(英文版)

基  金:Austrian Science Fund FWF,No.J4396;Wellcome Trust PhD Fellowship for Clinicians,No.UNS59491.

摘  要:The obesity pandemic has led to a significant increase in patients with metabolic dysfunction-associated fatty liver disease(MAFLD).While dyslipidemia,type 2 diabetes mellitus and cardiovascular diseases guide treatment in patients without signs of liver fibrosis,liver related morbidity and mortality becomes relevant for MAFLD’s progressive form,non-alcoholic steatohepatitis(NASH),and upon development of liver fibrosis.Statins should be prescribed in patients without significant fibrosis despite concomitant liver diseases but are underutilized in the real-world setting.Bariatric surgery,especially Y-Roux bypass,has been proven to be superior to conservative and/or medical treatment for weight loss and resolution of obesity-associated diseases,but comes at a low but existent risk of surgical complications,reoperations and very rarely,paradoxical progression of NASH.Once end-stage liver disease develops,obese patients benefit from liver transplantation(LT),but may be at increased risk of perioperative infectious complications.After LT,metabolic comorbidities are commonly observed,irrespective of the underlying liver disease,but MAFLD/NASH patients are at even higher risk of disease recurrence.Few studies with low patient numbers evaluated if,and when,bariatric surgery may be an option to avoid disease recurrence but more high-quality studies are needed to establish clear recommendations.In this review,we summarize the most recent literature on treatment options for MAFLD and NASH and highlight important considerations to tailor therapy to individual patient’s needs in light of their risk profile.

关 键 词:Metabolic dysfunction-associated fatty liver disease Non-alcoholic fatty liver disease Portal hypertension CIRRHOSIS Bariatric surgery METABOLISM 

分 类 号:R575.2[医药卫生—消化系统]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象